Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14681MR)

This product GTTS-WQ14681MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14681MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7332MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ1531MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ12114MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ13571MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ13030MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ10643MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ8342MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ565MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 62-71-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW